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In the last decade, two major scientiﬁc achievements have
deeply changed our understanding of the epidemiology, clinical
signiﬁcance and laboratory research of the human pathogen
Haemophilus inﬂuenzae: the dramatic effect of H. inﬂuenzae type
b (Hib) conjugate vaccines in preventing invasive infections due
to this organism in the early 1990s, and the publication of theH.
inﬂuenzae genome sequence in 1995, which has provided great
oportunities for research in the ﬁelds of gene expression and
function, evolutionary biology, pathogenicity and others [1–3].
In addition, in the last 5 years, acquisition of new antibiotic
resistance to drugs like ﬂuorquinolones and amoxicillin-
clavulanic acid has been described [4,5].
H. INFLUENZAE T YPE B CONJUGATE VACCINES
AND SEROT YPE REPL ACEMENT
Before vaccination, the annual European incidence rate of
invasive Hib diseases in children under 5 years of age was
between 20 and 60 per 100 000, with wide geographic varia-
tions. About 60% of cases were meningitis. Countries with high
vaccination coverage have experienced sharp reductions (90–
100%) in their Hib incidence. In 1998, the crude European
incidence (per 100 000 population) of Hib invasive disease for
children under 5 years, and children under 1 year was 1.28 and
2.88, respectively [6]. Several studies have indicated that Hib
carriage is reduced by vaccination with conjugate vaccine [7],
conferring so-called herd immunity, which may also explain the
reduction of Hib infections in non-vaccinated groups, like very
young and older children [8]. Although Hib is predominantly a
disease of childhood, infections can occur in the adult popula-
tion, who may serve as a continuing reservoir of infection for
susceptible individuals [6]. Hib conjugate vaccines differ in
biochemical composition and immunogenicity, and may vary in
their long-term efﬁcacy and effect on Hib carriage. It would be
advisable to maintain carriage surveillance of Hib and other
Haemophilus serotypes in populations with immunization
programs.
In the USA, after widespread use of conjugate vaccines in
the general population, the number of reported Hib invasive
disease cases has declined by 99% in the period 1987–97 making
feasible the goal to eliminate Hib disease [9]. However, re-
emergence of Hib invasive disease in a well-vaccinated popula-
tion in Alaska has been reported recently following a change in
Hib vaccine regimen; ongoing carriage and transmission of Hib
in the population contributed to disease resurgence [10].
The worldwide analysis of the Hib diseases burden, before
and after the Hib vaccine became available, has recently been
carried out in detail [11]. It is estimated that in the richest part of
the world, which can afford Hib vaccination programs, 38 000
cases of all Hib invasive diseases in children 0–4 years old are
prevented each year; worldwide ﬁgures are far less impressive as
only 8.5% of cases of Hib invasive infection in children (38 000
out of 445 000) are estimated to be prevented, not including
pneumonia [11]. According to the World Health Organization,
Hib still causes 3 million cases of serious disease and 400 000–
700 000 deaths per year in young children worldwide [11].
In the Hib post-vaccination era, accurate laboratory surveil-
lance of serotype should be carried out for all cases of invasive
H. inﬂuenzae disease. Serotype information is essential to [1]:
evaluate vaccine efﬁcacy and eventual vaccine failure cases
[2]; evaluate changes in the epidemiology of invasive infections
due to other capsule types and/or non-typeable strains. Invasive
H. inﬂuenzae infections including meningitis can occur in fully
Hib vaccinated children; this situation may or may not indicate a
possible case of Hib vaccine failure. Careful serotype evaluation
is needed; to avoid false-positive and false-negative results,
polymerase chain reaction (PCR)-based genotyping is available.
Although Hib disease now occurs primarily among under-
vaccinated children and infants too young to have completed
the primary series of vaccination, cases of true vaccine failure
occur [12]. A systematic evaluation of risk factors associated
with vaccine failure should always be carried out [9]. Among
the cases of vaccine failure, potentially predisposing host factors
like prematurity, malignancy and immunoglobulin deﬁciency
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are present in 20–40% of the cases [6]; in a substantial number of
cases, however, no apparent risk factors can be found.
The serotype speciﬁcity of Hib conjugate vaccines and their
protection against asymptomatic carriage have raised concerns
about the possibility of serotype replacement [6–8]. Theoreti-
cally, other serotypes and/or non-typeableH. inﬂuenzae isolates
may ﬁll the ecologic niche left vacant by Hib. Replacement
would take place ﬁrst in healthy vaccinated carriers followed by
an increasing number of invasive infections due to non-b
isolates. Although some reports suggested serotype replacement
[8,13,14] it has not been clearly demonstrated with Hib con-
jugate vaccines; the opposite seems true for pneumococcal
conjugate vaccines. The lack of serotype replacement after
widespread use of Hib conjugate vaccines may be the conse-
quence of the low prevalence of Hib carriage in children in the
prevaccination era (< 5%); some degree of non-b replacement,
however, may be expected, at least in countries with high
prevaccination Hib carriage.
A trend toward an increased incidence of H. inﬂuenzae
serotypes e and f has been noted, but this could be related to
increased attention and/or growing host risks factors (see
below) [13,14]. In Europe [6], the vast majority of non-b
strains causing invasive infections for the years 1996–98, were
non-capsulated (1998 incidence: 0.30 per 100 000, total; 0.26
per 100 000, children <15 years); the main clinical diagnostic
was septicemia, not meningitis as happened with Hib. In the
same period, there were 830 cases of non-capsulated invasive
infections, 522 type b and 114 of capsulated non-b (83 Hif, 25
Hie, six others) [6]. Available evidence indicates that the
epidemiology and clinical signiﬁcance of serotypes e and f
and others are far from being similar to the Hib [14]. A large
proportion of infections due to serotypes e and f occur in adults
with severe respiratory infections and other underlying diseases
[14]; when children are affected, the clinical pictures of types e
and f resemble those for type b [13,14]. Unfortunately, many
invasive H. inﬂuenzae strains remain untyped. In the last 5 years
we have identiﬁed 25 cases of invasive infections due to type f,
and 10 cases of type e in Spain. Only 50% and 25% of cases of
types e and f occurred in children<15 years of age, respectively;
severe underlying diseases were present in the 40% and 60% of
types e and f, respectively.
ANTIBIOTIC RESISTANCE
In most countries, there is a general trend to increasing con-
sumption of oral aminopenicillins and oral cephalosporins to
treat upper respiratory infections, particularly in children. It has
been suggested that not only the total amount of antibiotics
consumption, but also the proportion of aminopenicillins to
cephalosporins are important to select speciﬁc phenotypes of
antibiotic-resistant populations of bacteria [15]. It has been
assumed that the majority of H. inﬂuenzae strains resistant to
amoxicillin worldwide, produce plasmid-mediated TEM-1 b-
lactamase; ROB-1 b-lactamase has been detected in some
geographical areas [16].
With marked national and local differences, there has been a
steady upward trend in b-lactamase positivity of H. inﬂuenzae
isolated from community-acquired lower respiratory infections
[17–19]. Amoxicillin/clavulanic acid, however, has retained its
initial activity with little change. This may indicate that the
initial mechanism of ampicillin resistance, production of TEM-
1 b-lactamase, described almost 30 years ago in the ﬁrst ampi-
cillin-resistant strains, has evolved little over time to adapt to the
new antibiotic pressures posed by oral b-lactam antibiotics. This
is quite surprising as new antibiotic resistances have emerged in
this pathogen in a rapid response to antibiotic pressure, as has
happened with ﬂuorquinolones [4]. There is little information
available about the prevalence and types of b-lactamases present
in strains of H. inﬂuenzae isolated from respiratory infections;
more surveillance studies would be needed.
Modiﬁcations in the PBP targets of b-lactam antibiotics, as
has been the case for S. pneumoniae, could have been another
suitable mechanism of resistance forH. inﬂuenzae; however, few
(< 5%) of these strains are usually reported in large surveillance
studies [17–19]. This non-b-lactamase-mediated resistance
usually increases the MICs for amoxicillin/clavulanic acid
and third-generation cephalosporins, and would therefore be
an excellent mechanism of bacterial protection against anti-
biotic pressure, but for unknown reasons remains underdeve-
loped. Nevertheless, this kind of resistance phenotype might be
important for individual patients at special risk, as in the case of
cystic ﬁbrosis or chronic bronchitis patients receiving many
courses of b-lactam antibiotics.
In response to increased consumption of third-generation
cephalosporins, as seems to be the case of the USA, new
mechanisms of resistance may arise in which the MICs of these
cephalosporins would increase; in this particular situation, an
extended spectrum b-lactamase or PBP modiﬁcation should be
suspected [15]. However, third-generation cephalosporins are
currently so active against H. inﬂuenzae that subtle changes of
their antimicrobial activity would be difﬁcult to detect both
with the disk diffusion method and the MIC. Changes in other
less active cephalosporins, such as cefaclor or cefuroxime, may
be more sensitive. Increased MICs, including resistance, are
often seen with cefaclor; several theories have been suggested
for cefaclor resistance including hyperproduction of b-lacta-
mase and PBP modiﬁcation, without convincing laboratory
data. A recent paper has shown that cefaclor resistance in
Canadian H. inﬂuenzae strains correlates with ROB-1 b-lacta-
mase production [20].
In vitro, the b-lactamase inhibitor clavulanic acid reverses the
action of both TEM-1 and ROB-1 enzymes [21], but this
inhibitory effect decreases as the number of viable cells
increases. Comparative MICs, increasing the number of viable
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cells, show that production of b-lactamase enables big popula-
tions ofH. inﬂuenzae to survive in the presence of large amounts
of b-lactam antibiotics, particularly amoxicillin/clavulanic acid
and some cephalosporins, the so-called inoculum effect
(deﬁned as a four-fold or greater increase in MIC). In one
study, the MIC90 values of amoxicillin/clavulanic for a collec-
tion of H. inﬂuenzae increased from 2mg/L (104 cfu/mL) to
>16mg/L (106 cfu/mL) [22]. The biological consequences of
this phenomenon are poorly understood and would demand
further investigation.
For large numbers of infecting organisms, production of
TEM-1 b-lactamase may continue to be an effective bacterial
mechanism of resistance and survival. In one study of treatment
failure in otitis media, 49.2% of theH. inﬂuenzae strains causing
treatment failures produced b-lactamase; 65.6% of the patients
had been treated either with amoxicillin/clavulanic acid or oral
third-generation cephalosporins [23]. Other factors like anti-
biotic levels may also play a role. The number of viable infecting
cells is usually unknown. The standard inoculum size used for
MIC testing may or may not reproduce the actual infectious
process; but adjusting the inoculum size by turbidity alone may
be an unreliable method for accurate determination and repro-
ducibility of theMICs for b-lactam antibiotics; colony counting
should be performed [22]. Available data indicate that deter-
mination ofH. inﬂuenzae amoxicillin/clavulanic acid MICs, can
be method- and laboratory-dependent [24,25]; one study found
that the agreement between E test MICs and broth microdilu-
tion, two popular methods of susceptibility used in clinical
laboratories, was 31% [25].
In Escherichia coli as in H. inﬂuenzae, resistance to ampicillin
and amoxicillin is mainly caused by plasmid-encoded b-lacta-
mase TEM-1. From the early 1990s, however, it was apparent
that a small proportion of E. coli isolates were resistant to
amoxicillin/clavulanic acid [26]. In E. coli, the predominant
mechanisms of resistance to amoxicillin/clavulanic acid are
hyperproduction of TEM-1 b-lactamase (> 200 nmol of nitro-
ceﬁn hydrolized per min per mg of protein), production of
OXA-1 b-lactamase and production of inhibitor-resistant TEM
(IRT) enzymes [26]. The IRTenzymes are mutants of TEM-1
b-lactamase with amino acid substitutions, both in the promo-
ter and the structural gene, of TEM-1 b-lactamase; they cannot
be distinguished by isoelectric focusing because all have similar
pI (5.2–5.4). As a Gram-negative bacillus belonging to the
normal respiratory ﬂora of humans, exposed to selective pres-
sure of extensive oral treatments with aminopenicillins and
amoxicillin/clavulanic acid, development of new resistance
mechanisms to amoxicillin/clavulanic acid as in E. coli, may
have been postulated for H. inﬂuenzae.
In two independent US surveillance studies of antibiotic-
resistant H. inﬂuenzae in 1994 and 1995 [5,18], resistance to
amoxicillin/clavulanic was described at a very low frequency. In
one report, 17 out of 1537 clinical strains, and eight out of 1910
in the other one, were b-lactamase-positive and amoxicillin/
clavulanic acid-resistant (MIC 8/4mg/L). To date, the
mechanisms responsible for this resistance have not been
reported.
Another study further evaluated the eight amoxicillin/cla-
vulanic acid-resistant strains reported in one of the referred
publications [18]. Resistance was conﬁrmed for only one of the
strains in which double zones of growth were seen with both
the disk diffusion method and the E test [27]. Authors advised
against this very rare antibiotic resistance found in large sur-
veillance studies as these could be produced just by chance. The
most resistant part of the growth consisted of spheroplasts. The
use of culture media with high osmolality may be related to the
production of spheroplasts. Lack of reproducibility in MICs
were attributed to possible variations in inoculum size, presence
of spheroplasts and differences in potency of amoxicillin and
clavulanic acid in the commercial trays and E test [27]. Problems
with test reproducibility have also been noted in E. coli [26].
ACKNOWLEDGMENT
This work was supported in part by the Fis(98/20-01), Spanish
Ministry of Health.
REFERENCES
1. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus
influenzae type b meningitis after routine childhood immunisation
with conjugate vaccines. Lancet 1992; 340: 592–4.
2. Fleischmann RD, Adams MD, White O et al. Whole-genome
random sequencing and assembly of Haemophilus influenzae. Science
1995; 269: 496–512.
3. Moxon ER. Whole genome sequencing of pathogens: a new era
in microbiology. Trends Microbiol 1995; 3: 335–7.
4. Georgiou M, Munoz R, Roman F, Canto´n R, Go´mez-Lus R,
Campos J, De la Campa A. Ciprofloxacin-resistant Haemophilus
influenzae strains possess mutations in analogous positions of gyrA
and ParC. Antimicrob Agents Chemother 1996; 40: 1741–4.
5. Doern GV, Brueggemann AB, Pierce G, Holley HP, Rauch A.
Antibiotic resistance among clinical isolates of Haemophilus
influenzae in the United States in 1994and 1995 and detection
of b-lactamase-positive strains resistant to amoxicillin-clavulanate:
results of a National multicenter surveillance study. Antimicrob
Agents Chemother 1997; 41: 292–7.
6. Ramsay M. An evaluation of Haemophilus influenzae vaccination and
description of risk factors for Hib vaccine failure in Europe, 1996–1998.
Final report. Biomed II. European Community, 2000.
7. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon
ER. The impact of conjugate vaccines on carriage of Haemophilus
influenzae type b. J Infect Dis 1995; 171: 93–8.
8. Perdue DG, Bulkow LR, Gellin BG, Davidson M, Petersen Km,
Singleton RJ, Parkinson AJ. Invasive Haemophilus influenzae
diseases in Alaskan residents aged 10 years and older before and
after infant vaccination programs. JAMA 2000; 283: 3089–94.
9. Centers for Diseases Control. Progress toward eliminating Haemo-
philus influenzae type b disease among infants and children – United
States, 1987–97.MMWR 1998; 47: 993–8.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 287–290
Editorial 289
10. Galil K, Singleton R, Levine OS et al. Re-emergence of invasive
Haemophilus influenzae type b disease in a well-vaccinated
population in remote Alaska. J Infect Dis 1999; 179: 101–6.
11. Peltola H. Worldwide Haemophilus influenzae type b disease at the
beginning of the 21st century: global analysis of the disease burden
25 years after the use of the polysaccharide vaccine and a decade
after the advent of conjugates. Clin Microbiol Rev 2000; 13: 302–
17.
12. Booy R, Heath P, Slack M, Begg N, Moxon E. Vaccine failures
after primary immunisation with Haemophilus influenzae type-b
conjugate vaccine without booster. Lancet 1997; 349: 1197–202.
13. Waggoner-Fountain LA, Hendley JO, Cody EJ, Perriello VA,
Donowitz LG. The emergence of Haemophilus influenzae types e
and f as significant pathogens. Clin Infect Dis 1995; 21: 1322–4.
14. Urwin G, Krohn JA, Deaver-Robinson K, Wenger JD, Farley
MM. Invasive disease due to Haemophilus influenzae serotype f:
clinical and epidemiologic characteristics in the H. influenzae
serotype b vaccine era. Clin Infect Dis 1996; 22: 1069–76.
15. Baquero F. Trends in antibiotic resistance of respiratory pathogens:
an analysis and commentary on a collaborative study. J Antimicrob
Chemother 1996; 38(Suppl A): 117–32.
16. Scriver SR, Walmsley SL, Kau CL et al. Determination of
antimicrobial susceptibilities of Canadian isolates of Haemophilus
influenzae and characterization of their b-lactamases. Antimicrob
Agents Chemother 1994; 38: 1678–80.
17. Doern GV and The Alexander project collaborative group.
Antimicrobial resistance among lower respiratory tract isolates of
Haemophilus influenzae: results of a 1992–93 Western Europe and
USA collaborative study. J Antimicrob Chemother 1996; 38(Suppl.
A): 59–69.
18. Jones RN, Jacobs MR, Washington JA, Pfaller MAA. survey of
Haemophilus influenzae suceptibility to ten orally administered
agents: a 187 clinical laboratory center sample in the United
States, 1994–95. Diagn Microbiol Infect Dis 1997; 27: 75–84.
19. Sahm DF, Jones ME, Hickey ML, Diakun DR, Mani SV,
Thornsberry C. Resistance surveillance of Streptococcus pneumonia,.
Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and
Europe, 1997–98. J Antimicrob Chemother 2000; 45: 457–66.
20. Karlowsky JA, Verma G, Zhanel GG, Hoban Dj. Presence of
ROB-1 beta-lactamase correlates with cefaclor resistance among
recent isolates of Haemophilus influenzae. J Antimicrob Chemother
2000; 45: 871–5.
21. Balko T, Karlowsky JA, Palatnick LP, Zhanel GG, Hoban DJ.
Characterization of the inoculum effect with Haemophilus
influenzae and beta-lactams. Diagn Microbiol Infect Dis 1999; 33:
47–58.
22. Gould JM, Heidecker GJ, LiPuma JJ. Non-typeable Haemophilus
influenzae susceptibility: effect of inoculum size and b-lactamase
production. Diagn Microbiol Infect Dis 1996; 26: 95–8.
23. Gehanno P, N’Guyen L, Derriennic M, Pichon F, Goehrs JM,
Berche P. Pathogens isolated during treatment failures in otitis.
Pediatr Infect Dis J 1998; 17: 885–90.
24. Giger O, Mortensen JE, Clark RB, Evangelista A. Comparison of
five different susceptibility test methods for detecting antimicrobial
agent resistance among Haemophilus influenzae isolates. Diagn
Microbiol Infect Dis 1996; 24: 145–53.
25. Hoogkamp-Korstanje JA, Dirks-Go SI, Kabel P et al. Multicentre
in-vitro evaluation of the susceptibilty of Streptococcus pneumoniae,
Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin,
clarithromycin, co-amoxiclav and sparfloxacin. J Antimicrob Che-
mother 1997; 39: 411–4.
26. Stapleton P, Wu P, King A, Shannon K, French G, Phillips I.
Incidence and mechanisms of resistance to the combination of
amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents
Chemother 1995; 39: 2478–83.
27. Jacobs MR, Bajaksouzian S. Evaluation of Haemophilus influenzae
isolates with elevated MICs to amoxicillin/clavulanic acid. Diagn
Microbiol Infect Dis 1997; 28: 105–12.
 2001 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 7, 287–290
290 Clinical Microbiology and Infection, Volume 7 Number 6, June 2001
